카테터 관련 혈류감염 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측, 치료 유형별, 감염원별, 유통 채널별, 지역별, 경쟁별(2020-2030년)
Catheter Related Bloodstream Infection Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Treatment Type, By Source of Infection, By Distribution Channel, By Region and Competition, 2020-2030F
카테터 관련 혈류감염 세계 시장 규모는 2024년 16억 2,000만 달러로 평가되었고, 예측 기간 동안 5.62%의 연평균 복합 성장률(CAGR)로 2030년에는 22억 5,000만 달러에 달할 것으로 예상됩니다.
카테터 관련 혈류감염 세계 시장은 병원 내 감염, 특히 중심정맥 카테터와 관련된 감염 증가가 주요 요인으로 작용하고 있습니다. 카테터 관련 혈류감염은 중심정맥 카테터 사용으로 인한 가장 빈번하고 심각한 합병증 중 하나이며, 심각한 이환율, 사망률, 의료비용을 초래합니다. 특히 화학요법 등의 치료를 받고 있는 면역 결핍 환자 등 고위험군에서 혈류감염 발생률이 증가하면서 시장 성장을 더욱 촉진하고 있습니다. 카테터 관련 혈류감염의 치료를 복잡하게 만드는 항생제 내성에 대한 우려가 커지면서 첨단 진단 도구와 감염 예방 전략에 대한 수요가 증가하고 있습니다. 이러한 복합적인 요인들이 세계 카테터 관련 혈류감염 시장의 성장에 기여하고 있습니다.
| 시장 개요 |
| 예측 기간 |
2026-2030년 |
| 시장 규모 : 2024년 |
16억 2,000만 달러 |
| 시장 규모 : 2030년 |
22억 5,000만 달러 |
| CAGR(2025-2030년) |
5.62% |
| 급성장 부문 |
항균제 |
| 최대 시장 |
북미 |
시장 성장 촉진요인
병원 내 감염 증가
주요 시장 과제
첨단 감염 예방 기술의 고비용
주요 시장 동향
카테터 재료의 기술 발전
목차
제1장 개요
제2장 조사 방법
제3장 주요 요약
제4장 고객의 소리
제5장 세계의 카테터 관련 혈류감염 시장 전망
- 시장 규모와 예측
- 시장 점유율과 예측
- 치료 유형별(항균제, 항생제 잠금 요법)
- 감염원별(코아그라제 음성 포도상구균, 황색 포도상구균, 장내 그람 음성 간균, 효모, 장구균 및 연쇄구균, 녹농균, 기타)
- 유통 채널별(병원 약국, 소매 약국, 온라인 약국)
- 지역별
- 기업별(2024년)
- 시장 맵
제6장 북미의 카테터 관련 혈류감염 시장 전망
- 시장 규모와 예측
- 시장 점유율과 예측
- 북미 : 국가별 분석
제7장 유럽의 카테터 관련 혈류감염 시장 전망
- 시장 규모와 예측
- 시장 점유율과 예측
- 유럽 : 국가별 분석
제8장 아시아태평양의 카테터 관련 혈류감염 시장 전망
- 시장 규모와 예측
- 시장 점유율과 예측
- 아시아태평양 : 국가별 분석
제9장 남미의 카테터 관련 혈류감염 시장 전망
- 시장 규모와 예측
- 시장 점유율과 예측
- 남미 : 국가별 분석
제10장 중동 및 아프리카의 카테터 관련 혈류감염 시장 전망
- 시장 규모와 예측
- 시장 점유율과 예측
- 중동 및 아프리카 : 국가별 분석
제11장 시장 역학
제12장 시장 동향과 발전
- 인수합병(M&A)(해당하는 경우)
- 제품 발매(해당하는 경우)
제13장 Porter의 Five Forces 분석
- 산업내 경쟁
- 신규 참여 가능성
- 공급업체의 힘
- 고객의 힘
- 대체품의 위협
제14장 경쟁 구도
- Teva Pharmaceutical Industries Ltd.
- SteriMax Inc.
- Sanofi S.A.
- Pfizer Inc.
- Novartis AG
- Merck & Co., Inc.
- GSK plc
- Fresenius SE & Co. KGaA
- Eli Lilly and Company
- Aurobindo Pharma Limited
제15장 전략적 제안
제16장 리서치사에 대해 & 면책사항
LSH
Global Catheter Related Bloodstream Infection Market was valued at USD 1.62 Billion in 2024 and is expected to reach USD 2.25 Billion by 2030 with a CAGR of 5.62% during the forecast period. The global Catheter Related Bloodstream Infection market is primarily driven by the increasing prevalence of hospital-acquired infections, particularly those associated with central venous catheters. Catheter related bloodstream infections are among the most frequent and serious complications of central venous catheter use, leading to significant morbidity, mortality, and healthcare costs. The rising incidence of bloodstream infections, especially in high-risk groups like immunocompromised patients undergoing treatments such as chemotherapy, further fuels market growth. The growing concern over antibiotic resistance, which complicates the treatment of catheter related bloodstream infections, has led to a rising demand for advanced diagnostic tools and infection prevention strategies. These combined factors are contributing to the expansion of the global Catheter Related Bloodstream Infection market.
| Market Overview |
|---|
| Forecast Period | 2026-2030 |
| Market Size 2024 | USD 1.62 Billion |
| Market Size 2030 | USD 2.25 Billion |
| CAGR 2025-2030 | 5.62% |
| Fastest Growing Segment | Anti-microbial Agents |
| Largest Market | North America |
Key Market Drivers
Increasing Prevalence of Hospital-Acquired Infections
Hospital-acquired infections (HAIs) are one of the most significant health concerns in medical settings globally. Catheter-related bloodstream infections (CRBSIs) are one of the leading types of HAIs, and their rising prevalence plays a substantial role in driving the growth of the global Catheter Related Bloodstream Infection market. These infections occur when pathogens enter the bloodstream through central venous catheters, a common medical device used for administering medications, fluids, and nutrients to critically ill patients. The growing number of patients requiring invasive procedures such as surgeries, dialysis, and long-term intravenous treatments leads to an increase in catheter usage, thus elevating the risk of CRBSIs. This, in turn, results in an increased demand for effective infection prevention and diagnostic solutions. According to WHO, On average, approximately 1 in 10 patients experiences healthcare-associated infections (HAIs); however, the incidence is notably higher in low- and middle-income countries, as well as among high-risk patients, such as those in intensive care units. According to a 2023 study by Balasubramanian et al., around 136 million cases of healthcare-associated antibiotic-resistant infections occur globally each year. In Europe, the impact of the six most common HAIs was found to be twice as significant as the combined burden of 32 other infectious diseases, in terms of disability and premature mortality. Additionally, it was estimated that 63.5% of infections caused by antibiotic-resistant bacteria are associated with healthcare settings.
Key Market Challenges
High Cost of Advanced Infection Prevention Technologies
One of the significant challenges in the global Catheter Related Bloodstream Infection market is the high cost of advanced infection prevention technologies. While innovative solutions such as antimicrobial-coated catheters, rapid diagnostic tools, and biofilm-resistant materials have proven effective in reducing infection rates, these technologies often come with a premium price. This cost barrier can be a challenge, especially in low-resource healthcare settings or emerging markets where budget constraints are a significant concern. Hospitals and healthcare providers may be hesitant to adopt these advanced solutions if they face financial limitations, despite the long-term benefits in terms of improved patient outcomes and reduced healthcare costs. The cost of training healthcare staff to effectively use these advanced technologies and maintain infection control protocols further compounds the financial burden on healthcare systems, making it difficult for some institutions to fully embrace these innovations.
Key Market Trends
Technological Advancements in Catheter Materials
Innovations in catheter design and material science are also contributing to the growth of the catheter-related bloodstream infection market. One significant development has been the introduction of antimicrobial-coated catheters, which are designed to reduce the risk of infection by inhibiting the growth of bacteria and other pathogens on the surface of the catheter. These catheters have been shown to significantly decrease the incidence of catheter-related bloodstream infections, especially in high-risk patient populations. In January 2025, Autonomix Medical, Inc. announced that it has achieved "design lock" for its Application Specific Integrated Circuits (ASIC) microchip. This milestone follows the successful completion of in vivo preclinical testing and extensive bench testing, marking continued progress toward the Company's U.S. pivotal trial.
The development of biofilm-resistant materials, which prevent the formation of bacterial biofilms on catheter surfaces, is further enhancing the safety and efficacy of catheters. As these technologies continue to advance, the demand for these more sophisticated catheter products is likely to grow, driving market expansion.
Key Market Players
- Teva Pharmaceutical Industries Ltd.
- SteriMax Inc.
- Sanofi S.A.
- Pfizer Inc.
- Novartis AG
- Merck & Co., Inc.
- GSK plc
- Fresenius SE & Co. KGaA
- Eli Lilly and Company
- Aurobindo Pharma Limited
Report Scope:
In this report, the Global Catheter Related Bloodstream Infection Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Catheter Related Bloodstream Infection Market, By Treatment Type:
- Anti-microbial Agents
- Antibiotic Lock Therapy
Catheter Related Bloodstream Infection Market, By Source of Infection:
- Coagulase-negative Staphylococcus
- S. Aureus
- Enteric Gram-negative Bacilli
- Yeasts
- Enterococci & Streptococci
- Pseudomonas
- Others
Catheter Related Bloodstream Infection Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Catheter Related Bloodstream Infection Market, By Region:
- North America
- United States
- Canada
- Mexico
- Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
- Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Catheter Related Bloodstream Infection Market.
Available Customizations:
Global Catheter Related Bloodstream Infection market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
- 1.1. Market Definition
- 1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations
2. Research Methodology
- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validations
- 2.7. Assumptions and Limitations
3. Executive Summary
- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Catheter Related Bloodstream Infection Market Outlook
- 5.1. Market Size & Forecast
- 5.2. Market Share & Forecast
- 5.2.1. By Treatment Type (Anti-microbial Agents and Antibiotic Lock Therapy)
- 5.2.2. By Source of Infection (Coagulase-negative Staphylococcus, S. Aureus, Enteric Gram-negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas, and Others)
- 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)
- 5.2.4. By Region
- 5.2.5. By Company (2024)
- 5.3. Market Map
6. North America Catheter Related Bloodstream Infection Market Outlook
- 6.1. Market Size & Forecast
- 6.2. Market Share & Forecast
- 6.2.1. By Treatment Type
- 6.2.2. By Source of Infection
- 6.2.3. By Distribution Channel
- 6.2.4. By Country
- 6.3. North America: Country Analysis
- 6.3.1. United States Catheter Related Bloodstream Infection Market Outlook
- 6.3.1.1. Market Size & Forecast
- 6.3.1.2. Market Share & Forecast
- 6.3.1.2.1. By Treatment Type
- 6.3.1.2.2. By Source of Infection
- 6.3.1.2.3. By Distribution Channel
- 6.3.2. Canada Catheter Related Bloodstream Infection Market Outlook
- 6.3.2.1. Market Size & Forecast
- 6.3.2.2. Market Share & Forecast
- 6.3.2.2.1. By Treatment Type
- 6.3.2.2.2. By Source of Infection
- 6.3.2.2.3. By Distribution Channel
- 6.3.3. Mexico Catheter Related Bloodstream Infection Market Outlook
- 6.3.3.1. Market Size & Forecast
- 6.3.3.2. Market Share & Forecast
- 6.3.3.2.1. By Treatment Type
- 6.3.3.2.2. By Source of Infection
- 6.3.3.2.3. By Distribution Channel
7. Europe Catheter Related Bloodstream Infection Market Outlook
- 7.1. Market Size & Forecast
- 7.2. Market Share & Forecast
- 7.2.1. By Treatment Type
- 7.2.2. By Source of Infection
- 7.2.3. By Distribution Channel
- 7.2.4. By Country
- 7.3. Europe: Country Analysis
- 7.3.1. Germany Catheter Related Bloodstream Infection Market Outlook
- 7.3.1.1. Market Size & Forecast
- 7.3.1.2. Market Share & Forecast
- 7.3.1.2.1. By Treatment Type
- 7.3.1.2.2. By Source of Infection
- 7.3.1.2.3. By Distribution Channel
- 7.3.2. United Kingdom Catheter Related Bloodstream Infection Market Outlook
- 7.3.2.1. Market Size & Forecast
- 7.3.2.2. Market Share & Forecast
- 7.3.2.2.1. By Treatment Type
- 7.3.2.2.2. By Source of Infection
- 7.3.2.2.3. By Distribution Channel
- 7.3.3. Italy Catheter Related Bloodstream Infection Market Outlook
- 7.3.3.1. Market Size & Forecast
- 7.3.3.2. Market Share & Forecast
- 7.3.3.2.1. By Treatment Type
- 7.3.3.2.2. By Source of Infection
- 7.3.3.2.3. By Distribution Channel
- 7.3.4. France Catheter Related Bloodstream Infection Market Outlook
- 7.3.4.1. Market Size & Forecast
- 7.3.4.2. Market Share & Forecast
- 7.3.4.2.1. By Treatment Type
- 7.3.4.2.2. By Source of Infection
- 7.3.4.2.3. By Distribution Channel
- 7.3.5. Spain Catheter Related Bloodstream Infection Market Outlook
- 7.3.5.1. Market Size & Forecast
- 7.3.5.2. Market Share & Forecast
- 7.3.5.2.1. By Treatment Type
- 7.3.5.2.2. By Source of Infection
- 7.3.5.2.3. By Distribution Channel
8. Asia-Pacific Catheter Related Bloodstream Infection Market Outlook
- 8.1. Market Size & Forecast
- 8.2. Market Share & Forecast
- 8.2.1. By Treatment Type
- 8.2.2. By Source of Infection
- 8.2.3. By Distribution Channel
- 8.2.4. By Country
- 8.3. Asia-Pacific: Country Analysis
- 8.3.1. China Catheter Related Bloodstream Infection Market Outlook
- 8.3.1.1. Market Size & Forecast
- 8.3.1.2. Market Share & Forecast
- 8.3.1.2.1. By Treatment Type
- 8.3.1.2.2. By Source of Infection
- 8.3.1.2.3. By Distribution Channel
- 8.3.2. India Catheter Related Bloodstream Infection Market Outlook
- 8.3.2.1. Market Size & Forecast
- 8.3.2.2. Market Share & Forecast
- 8.3.2.2.1. By Treatment Type
- 8.3.2.2.2. By Source of Infection
- 8.3.2.2.3. By Distribution Channel
- 8.3.3. Japan Catheter Related Bloodstream Infection Market Outlook
- 8.3.3.1. Market Size & Forecast
- 8.3.3.2. Market Share & Forecast
- 8.3.3.2.1. By Treatment Type
- 8.3.3.2.2. By Source of Infection
- 8.3.3.2.3. By Distribution Channel
- 8.3.4. South Korea Catheter Related Bloodstream Infection Market Outlook
- 8.3.4.1. Market Size & Forecast
- 8.3.4.2. Market Share & Forecast
- 8.3.4.2.1. By Treatment Type
- 8.3.4.2.2. By Source of Infection
- 8.3.4.2.3. By Distribution Channel
- 8.3.5. Australia Catheter Related Bloodstream Infection Market Outlook
- 8.3.5.1. Market Size & Forecast
- 8.3.5.2. Market Share & Forecast
- 8.3.5.2.1. By Treatment Type
- 8.3.5.2.2. By Source of Infection
- 8.3.5.2.3. By Distribution Channel
9. South America Catheter Related Bloodstream Infection Market Outlook
- 9.1. Market Size & Forecast
- 9.2. Market Share & Forecast
- 9.2.1. By Treatment Type
- 9.2.2. By Source of Infection
- 9.2.3. By Distribution Channel
- 9.2.4. By Country
- 9.3. South America: Country Analysis
- 9.3.1. Brazil Catheter Related Bloodstream Infection Market Outlook
- 9.3.1.1. Market Size & Forecast
- 9.3.1.2. Market Share & Forecast
- 9.3.1.2.1. By Treatment Type
- 9.3.1.2.2. By Source of Infection
- 9.3.1.2.3. By Distribution Channel
- 9.3.2. Argentina Catheter Related Bloodstream Infection Market Outlook
- 9.3.2.1. Market Size & Forecast
- 9.3.2.2. Market Share & Forecast
- 9.3.2.2.1. By Treatment Type
- 9.3.2.2.2. By Source of Infection
- 9.3.2.2.3. By Distribution Channel
- 9.3.3. Colombia Catheter Related Bloodstream Infection Market Outlook
- 9.3.3.1. Market Size & Forecast
- 9.3.3.2. Market Share & Forecast
- 9.3.3.2.1. By Treatment Type
- 9.3.3.2.2. By Source of Infection
- 9.3.3.2.3. By Distribution Channel
10. Middle East and Africa Catheter Related Bloodstream Infection Market Outlook
- 10.1. Market Size & Forecast
- 10.2. Market Share & Forecast
- 10.2.1. By Treatment Type
- 10.2.2. By Source of Infection
- 10.2.3. By Distribution Channel
- 10.2.4. By Country
- 10.3. MEA: Country Analysis
- 10.3.1. South Africa Catheter Related Bloodstream Infection Market Outlook
- 10.3.1.1. Market Size & Forecast
- 10.3.1.2. Market Share & Forecast
- 10.3.1.2.1. By Treatment Type
- 10.3.1.2.2. By Source of Infection
- 10.3.1.2.3. By Distribution Channel
- 10.3.2. Saudi Arabia Catheter Related Bloodstream Infection Market Outlook
- 10.3.2.1. Market Size & Forecast
- 10.3.2.2. Market Share & Forecast
- 10.3.2.2.1. By Treatment Type
- 10.3.2.2.2. By Source of Infection
- 10.3.2.2.3. By Distribution Channel
- 10.3.3. UAE Catheter Related Bloodstream Infection Market Outlook
- 10.3.3.1. Market Size & Forecast
- 10.3.3.2. Market Share & Forecast
- 10.3.3.2.1. By Treatment Type
- 10.3.3.2.2. By Source of Infection
- 10.3.3.2.3. By Distribution Channel
11. Market Dynamics
- 11.1. Drivers
- 11.2. Challenges
12. Market Trends & Developments
- 12.1. Merger & Acquisition (If Any)
- 12.2. Product Launches (If Any)
- 12.3. Recent Developments
13. Porter's Five Forces Analysis
- 13.1. Competition in the Industry
- 13.2. Potential of New Entrants
- 13.3. Power of Suppliers
- 13.4. Power of Customers
- 13.5. Threat of Substitute Products
14. Competitive Landscape
- 14.1. Teva Pharmaceutical Industries Ltd.
- 14.1.1. Business Overview
- 14.1.2. Company Snapshot
- 14.1.3. Products & Services
- 14.1.4. Financials (As Reported)
- 14.1.5. Recent Developments
- 14.1.6. Key Personnel Details
- 14.1.7. SWOT Analysis
- 14.2. SteriMax Inc.
- 14.3. Sanofi S.A.
- 14.4. Pfizer Inc.
- 14.5. Novartis AG
- 14.6. Merck & Co., Inc.
- 14.7. GSK plc
- 14.8. Fresenius SE & Co. KGaA
- 14.9. Eli Lilly and Company
- 14.10. Aurobindo Pharma Limited
15. Strategic Recommendations
16. About Us & Disclaimer
